University of Minnesota Medical School researchers have shown that reducing chronic inflammation can significantly protect against age-related macular degeneration (AMD)-like pathology in preclinical ...

The overall dry AMD market size in the US is anticipated to increase, due to the uptake of recently approved therapies, the launch of emerging therapies such as Gildeuretinol (Alkeus Pharmaceuticals), ...

A first-of-its-kind trial is testing adult stem cell transplants for advanced dry macular degeneration. Early results show the treatment is safe and can significantly improve vision, even in severely ...

University of Minnesota Medical School researchers have shown that reducing chronic inflammation can significantly ...

A wireless implant helped patients with severe macular degeneration regain usable vision. The results point toward a new ...

As we age, our vision undergoes natural changes, including difficulty focusing on near objects (presbyopia) and reduced light ...

Age-related macular degeneration (AMD) is one of the leading causes of vision loss among adults over 65. This condition ...

ANNX advances tanruprubart for Guillain-Barré syndrome, with an EMA filing planned for January 2026 and ongoing FDA ...

Coave Therapeutics has announced its lead gene therapy program, CoTx-101, for the treatment of retinal vascular diseases, ...

The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...

In a first-in-human phase 1/2a clinical trial, researchers used adult stem cells to help restore vision in people with age-related macular degeneration. In the United States, age-related macular degen ...

First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing ...